Amarin Corp. ADR (AMRN)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

GEMINI HOUSE ELY CAMBRIDGESHIRE, UNITED KINGDOM FK7 9JQ

Amarin Corp. focuses on the research, development and commercialization of novel drugs for treatment of central nervous system disorders. This neuroscience company has headquarters in London and a R&D facility in Scotland. Its lead product, Miraxion, is in phase III development for Huntington's disease.

Data as of 2020-10-17
Market Cap2.002 Billion Shares Outstanding388.673 Million Avg 30-day Volume8.648 Million
P/E Ratio Dividend Yield EPS-0.06
Price/Sales4.634 Price cash flow ratio101.0 Price free cash flow ratio-522.0
Book Value1.53 Price to Tangible Book3.44 Alpha0.05
Short Interest Ratio % Short Interest to Float R-squared0.043824
BETA2.8066 52-week High/Low26.12 / 3.36 Stddev0.575775
View SEC Filings from AMRN instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 5 3 66.67% 3 (0.2%) 3 (0.19%) 0.0%
Funds Holding: 274 299 -8.36% 74 (4.83%) 80 (5.12%) -7.5%
13F shares: 161.832 Million 169.703 Million -4.64% 105.099 Million 112.334 Million -6.44%
% Ownership 41.6369 46.9828 -11.38% 27.0404 31.1002 -13.05%
New Positions: 49 51 -3.92% 20 15 33.33%
Increased Positions 92 114 -19.3% 21 30 -30.0%
Closed Positions 68 68 0.0% 25 20 25.0%
Reduced Positions 60 80 -25.0% 19 25 -24.0%
Total Calls 9.103 Million 28.284 Million -67.82% 2.441 Million 7.843 Million -68.87%
Total Puts 9.096 Million 10.856 Million -16.22% 2.246 Million 2.28 Million -1.51%
PUT/CALL Ratio 1.0 0.38 163.16% 0.92 0.29 217.24%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding AMRN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AMRN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

52.5 Thousand total shares from 20 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KENNEDY JOSEPH T GENERAL COUNSEL

209,269 2020-09-30 10

THERO JOHN F PRESIDENT AND CEO

2,542,933 2020-09-30 14

KETCHUM STEVEN B CHIEF SCIENTIFIC OFFICER

526,854 2020-09-30 10

KALB MICHAEL WAYNE SVP AND CFO

96,913 2020-09-30 11

BERG AARON CHIEF COMMERCIAL OFFICER

212,942 2020-09-30 11

VAN HEEK G JAN

0 2020-07-13 1

ZAKRZEWSKI JOSEPH S

0 2020-07-13 3

O'SULLIVAN PATRICK J

0 2020-07-13 1

EKMAN LARS

0 2020-07-13 3

PETERSON KRISTINE

0 2020-07-13 1

STACK DAVID M

0 2020-07-13 1

SALYER MARK CHIEF COMMERCIAL OFFICER

  • Officer
0 2018-02-01 0

HEALY JAMES

  • Director
0 2016-07-11 0

FARRELL MICHAEL JAMES VP, FINANCE

  • Officer
30,190 2016-01-31 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP III LLC

ISALY SAMUEL D

  • Director
600,000 2012-09-04 0

GORDON CARL L

  • Director
600,000 2012-09-04 0

SEDLACK STUART D SENIOR VICE PRESIDENT

  • Officer
0 2012-07-26 0

HUFF PAUL CHIEF COMMERCIAL OFFICER

  • Officer
0 2012-07-26 0

ANDERSON JOSEPH

  • Director
0 2012-07-10 0

ABINGWORTH LLP

  • 10% Owner
No longer subject to file 2012-04-17 0

AHLHOLM FREDERICK W VICE PRESIDENT FINANCE

  • Officer
0 2012-02-01 0

SONI PARESH SVP AND HEAD OF DEVELOPMENT

  • Officer
0 2012-02-01 0

FOUNTAIN HEALTHCARE PARTNERS LTD.

  • Director
2,517,391 2011-09-30 0

FEIGAL DAVID W JR

  • Director
0 2011-07-12 0

SOFINNOVA VENTURE PARTNERS VII L P

SOFINNOVA MANAGEMENT VII, L.L.C.

HEALY JAMES

POWELL MICHAEL

BUATOIS ERIC

  • Director
  • 10% Owner
8,513,388 2011-03-29 0

ROGAN MANUS

  • Director
17,391 2011-01-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

KALB MICHAEL WAYNE SVP AND CFO

2020-10-02 20:05:04 -0400 2020-09-30 M 1,528 d 16,805 direct

BERG AARON CHIEF COMMERCIAL OFFICER

2020-10-02 20:05:39 -0400 2020-09-30 M 1,528 d 16,805 direct

BERG AARON CHIEF COMMERCIAL OFFICER

2020-10-02 20:05:39 -0400 2020-09-30 M 1,528 a 214,448 direct -1.581 1.581 4.9407 3 -1.581 2

THERO JOHN F PRESIDENT AND CEO

2020-10-02 20:03:08 -0400 2020-09-30 M 6,737 d 74,096 direct

THERO JOHN F PRESIDENT AND CEO

2020-10-02 20:03:08 -0400 2020-09-30 M 6,737 a 2,536,196 direct -1.581 1.581 4.9407 3 -1.581 2

KENNEDY JOSEPH T GENERAL COUNSEL

2020-10-02 20:03:51 -0400 2020-09-30 M 1,806 a 209,269 direct -1.581 1.581 4.9407 3 -1.581 2

KETCHUM STEVEN B CHIEF SCIENTIFIC OFFICER

2020-10-02 20:04:26 -0400 2020-09-30 M 1,528 d 16,805 direct

KETCHUM STEVEN B CHIEF SCIENTIFIC OFFICER

2020-10-02 20:04:26 -0400 2020-09-30 M 1,528 a 526,832 direct -1.581 1.581 4.9407 3 -1.581 2

KALB MICHAEL WAYNE SVP AND CFO

2020-10-02 20:05:04 -0400 2020-09-30 M 1,528 a 96,913 direct -1.581 1.581 4.9407 3 -1.581 2

BERG AARON CHIEF COMMERCIAL OFFICER

2020-10-02 20:05:39 -0400 2020-09-30 M 1,528 d 16,805 direct

BERG AARON CHIEF COMMERCIAL OFFICER

2020-10-02 20:05:39 -0400 2020-09-30 M 1,528 a 212,920 direct -1.581 1.581 4.9407 3 -1.581 2

THERO JOHN F PRESIDENT AND CEO

2020-10-02 20:03:08 -0400 2020-09-30 M 6,737 d 74,096 direct

KENNEDY JOSEPH T GENERAL COUNSEL

2020-10-02 20:03:51 -0400 2020-09-30 M 1,806 d 19,860 direct

KENNEDY JOSEPH T GENERAL COUNSEL

2020-10-02 20:03:51 -0400 2020-09-30 M 1,806 a 207,463 direct -1.581 1.581 4.9407 3 -1.581 2

KETCHUM STEVEN B CHIEF SCIENTIFIC OFFICER

2020-10-02 20:04:26 -0400 2020-09-30 F 1,506 $4.04 d 526,854 direct -1.581 1.581 4.9407 3 -1.581 2

KALB MICHAEL WAYNE SVP AND CFO

2020-10-02 20:05:04 -0400 2020-09-30 M 1,528 d 16,805 direct

KALB MICHAEL WAYNE SVP AND CFO

2020-10-02 20:05:04 -0400 2020-09-30 M 1,528 a 95,385 direct -1.581 1.581 4.9407 3 -1.581 2

BERG AARON CHIEF COMMERCIAL OFFICER

2020-10-02 20:05:39 -0400 2020-09-30 F 1,506 $4.04 d 212,942 direct -1.581 1.581 4.9407 3 -1.581 2

THERO JOHN F PRESIDENT AND CEO

2020-10-02 20:03:08 -0400 2020-09-30 M 6,737 a 2,542,933 direct -1.581 1.581 4.9407 3 -1.581 2

KENNEDY JOSEPH T GENERAL COUNSEL

2020-10-02 20:03:51 -0400 2020-09-30 M 1,806 d 19,860 direct

KETCHUM STEVEN B CHIEF SCIENTIFIC OFFICER

2020-10-02 20:04:26 -0400 2020-09-30 M 1,528 d 16,805 direct

KETCHUM STEVEN B CHIEF SCIENTIFIC OFFICER

2020-10-02 20:04:26 -0400 2020-09-30 M 1,528 a 528,360 direct -1.581 1.581 4.9407 3 -1.581 2

BERG AARON CHIEF COMMERCIAL OFFICER

2020-09-02 20:07:37 -0400 2020-08-31 M 1,527 a 211,371 direct -5.7018 -10.5263 12.9386 16.4474 24 -20.1754 15

THERO JOHN F PRESIDENT AND CEO

2020-09-02 20:01:43 -0400 2020-08-31 M 6,736 d 80,833 direct

THERO JOHN F PRESIDENT AND CEO

2020-09-02 20:01:43 -0400 2020-08-31 M 6,736 a 2,528,025 direct -5.7018 -10.5263 12.9386 16.4474 24 -20.1754 15

KENNEDY JOSEPH T GENERAL COUNSEL

2020-09-02 20:02:16 -0400 2020-08-31 F 1,902 $7.36 d 205,657 direct -5.7018 -10.5263 12.9386 16.4474 24 -20.1754 15

KETCHUM STEVEN B CHIEF SCIENTIFIC OFFICER

2020-09-02 20:04:53 -0400 2020-08-31 M 1,527 d 18,333 direct

KETCHUM STEVEN B CHIEF SCIENTIFIC OFFICER

2020-09-02 20:04:53 -0400 2020-08-31 M 1,527 a 526,810 direct -5.7018 -10.5263 12.9386 16.4474 24 -20.1754 15

KALB MICHAEL WAYNE SVP AND CFO

2020-09-02 20:06:59 -0400 2020-08-31 M 1,527 d 18,333 direct

KALB MICHAEL WAYNE SVP AND CFO

2020-09-02 20:06:59 -0400 2020-08-31 M 1,527 a 93,826 direct -5.7018 -10.5263 12.9386 16.4474 24 -20.1754 15

BERG AARON CHIEF COMMERCIAL OFFICER

2020-09-02 20:07:37 -0400 2020-08-31 F 1,506 $7.36 d 211,392 direct -5.7018 -10.5263 12.9386 16.4474 24 -20.1754 15

THERO JOHN F PRESIDENT AND CEO

2020-09-02 20:01:43 -0400 2020-08-31 F 5,302 $7.36 d 2,529,459 direct -5.7018 -10.5263 12.9386 16.4474 24 -20.1754 15

KENNEDY JOSEPH T GENERAL COUNSEL

2020-09-02 20:02:16 -0400 2020-08-31 M 1,805 d 21,666 direct

KENNEDY JOSEPH T GENERAL COUNSEL

2020-09-02 20:02:16 -0400 2020-08-31 M 1,805 a 207,559 direct -5.7018 -10.5263 12.9386 16.4474 24 -20.1754 15

KETCHUM STEVEN B CHIEF SCIENTIFIC OFFICER

2020-09-02 20:04:53 -0400 2020-08-31 M 1,527 d 18,333 direct

KETCHUM STEVEN B CHIEF SCIENTIFIC OFFICER

2020-09-02 20:04:53 -0400 2020-08-31 M 1,527 a 525,283 direct -5.7018 -10.5263 12.9386 16.4474 24 -20.1754 15

KALB MICHAEL WAYNE SVP AND CFO

2020-09-02 20:06:59 -0400 2020-08-31 F 1,496 $7.36 d 93,857 direct -5.7018 -10.5263 12.9386 16.4474 24 -20.1754 15

BERG AARON CHIEF COMMERCIAL OFFICER

2020-09-02 20:07:37 -0400 2020-08-31 M 1,527 d 18,333 direct

BERG AARON CHIEF COMMERCIAL OFFICER

2020-09-02 20:07:37 -0400 2020-08-31 M 1,527 a 212,898 direct -5.7018 -10.5263 12.9386 16.4474 24 -20.1754 15

THERO JOHN F PRESIDENT AND CEO

2020-09-02 20:01:43 -0400 2020-08-31 M 6,736 d 80,833 direct

THERO JOHN F PRESIDENT AND CEO

2020-09-02 20:01:43 -0400 2020-08-31 M 6,736 a 2,534,761 direct -5.7018 -10.5263 12.9386 16.4474 24 -20.1754 15

KENNEDY JOSEPH T GENERAL COUNSEL

2020-09-02 20:02:16 -0400 2020-08-31 M 1,805 d 21,666 direct

KENNEDY JOSEPH T GENERAL COUNSEL

2020-09-02 20:02:16 -0400 2020-08-31 M 1,805 a 205,754 direct -5.7018 -10.5263 12.9386 16.4474 24 -20.1754 15

KETCHUM STEVEN B CHIEF SCIENTIFIC OFFICER

2020-09-02 20:04:53 -0400 2020-08-31 F 1,506 $7.36 d 525,304 direct -5.7018 -10.5263 12.9386 16.4474 24 -20.1754 15

KALB MICHAEL WAYNE SVP AND CFO

2020-09-02 20:06:59 -0400 2020-08-31 M 1,527 d 18,333 direct

KALB MICHAEL WAYNE SVP AND CFO

2020-09-02 20:06:59 -0400 2020-08-31 M 1,527 a 95,353 direct -5.7018 -10.5263 12.9386 16.4474 24 -20.1754 15

BERG AARON CHIEF COMMERCIAL OFFICER

2020-09-02 20:07:37 -0400 2020-08-31 M 1,527 d 18,333 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments